OUD (Opioid Use Disorder) Target Trial
NCT06585709
Recruiting
In this research study the investigators will work with 80-participants with opioid use disorder who are starting treatment with the medication buprenorphine and are trying to quit using opioids. The investigators are trying to learn two things: 1. Can an MRI brain marker be used to predict which participants will be successful in quitting opioids with buprenorphine? 2. Does adjunctive treatment with repetitive Transcranial Magnetic Stimulation (rTMS) help people quit using opioids more than a... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Duke University, Durham, North Carolina
Conditions: Opioid Use Disorder
Register for Updates
A Bundled Intervention
NCT06593093
Recruiting
Opioid overdose deaths have reached historically high records in the United States and are particularly concentrated among patients after emergency department (ED) discharge. Evidence-based treatment modules to reduce repeat opioid overdose and mortality are lacking in this patient population. A bundled intervention is proposed, including telehealth, peer support specialist, buprenorphine, and linkage for definitive care, that is designed to increase treatment uptake in this patient population p... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
06/24/2025
Locations: UAB, Birmingham, Alabama
Conditions: Opioid Use Disorder, Opioid Overdose
Register for Updates
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
NCT06632327
Recruiting
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patie... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +327 locations
Conditions: Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Register for Updates
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
NCT06632977
Recruiting
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) abnormalities or mutations in their cancer. Valemetostat tosylate is in a class of medications called EZH1/EZH2 inhibitors. It blocks proteins called EZH1 and EZH2, which may help slow or stop the sprea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Banner University Medical Center - Tucson, Tucson, Arizona +42 locations
Conditions: Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
Register for Updates
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
NCT06657768
Recruiting
The main purpose of this study is to evaluate the safety and tolerability of the study drug known as LY4006895. Part A will administer a single-ascending dose in healthy participants or Part B will administer multiple-ascending doses in participants with early symptomatic Alzheimer's Disease (AD). Blood tests will be performed to check how much LY4006895 gets into the bloodstream and how long it takes the body to eliminate it. This is a 2-part study and will last approximately 29 weeks for Par... Read More
Gender:
ALL
Ages:
Between 45 years and 85 years
Trial Updated:
06/24/2025
Locations: Collaborative Neuroscience Network - CNS, Los Alamitos, California +6 locations
Conditions: Alzheimer Disease, Healthy
Register for Updates
A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
NCT06659549
Recruiting
Age-related macular degeneration (AMD) affects millions of elderly patients. When advanced, there is Geographic Atrophy (GA) in the retina. This means that there is an area with a loss of light-sensitive cells, called photoreceptors. That part of the retina can no longer see. Atrophy begins as a small spot in the retina distant from the fovea which is the part of the retina responsible for sharp central vision. The GA grows, and when it reaches the fovea, vision is severely diminished, and detai... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
06/24/2025
Locations: Retina-Vitreous Associates Medical Group, Beverly Hills, California +11 locations
Conditions: Geographic Atrophy of the Macula
Register for Updates
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
NCT06661720
Recruiting
This phase III trial compares the effect of adding tivozanib to standard therapy pembrolizumab versus pembrolizumab alone for the treatment of patients with high-risk renal cell carcinoma (RCC). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Tivozanib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal prot... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Cancer Center at Saint Joseph's, Phoenix, Arizona +207 locations
Conditions: Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Stage II Renal Pelvis Cancer AJCC V8, Stage III Renal Pelvis Cancer AJCC V8
Register for Updates
Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial
NCT06671912
Recruiting
This phase III trial compares the effect of low dose tamoxifen to usual hormonal therapy, including aromatase inhibitors, in treating post-menopausal women with hormone positive, HER2 negative early stage breast cancer. Tamoxifen is in a class of medications known as antiestrogens. It blocks the activity of estrogen (a female hormone) in the breast. This may stop the growth of some breast tumors that need estrogen to grow. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, pre... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Katmai Oncology Group, Anchorage, Alaska +420 locations
Conditions: Anatomic Stage 0 Breast Cancer AJCC V8, Anatomic Stage 1 Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Estrogen Receptor-Positive Breast Carcinoma, HER2-Negative Breast Carcinoma
Register for Updates
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
NCT06682806
Recruiting
This is a Phase 2 an open-label, multi-center study to determine the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and anti-tumor activity of PRT3789 in combination with pembrolizumab in patients with advanced, recurrent or metastatic solid tumors with a SMARCA4 mutation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: Florida Cancer Specialists, West Palm Beach, Florida +8 locations
Conditions: Advanced Solid Tumor, Esophageal Cancer, Metastatic Solid Tumor, Non-small Cell Lung Cancers, SMARCA4 Gene Mutation
Register for Updates
ClAmpless, Sutureless PartIAl Nephrectomy for Renal Masses
NCT06722807
Recruiting
During partial nephrectomy surgery, efforts at minimizing ischemia while maximizing renal parenchymal volume are desirable to preserve renal function1,2. Not only clamping of the hilum but the renorrhaphy portion of the procedure also can have a significant negative impact on renal function3-5. It is possible to perform this procedure without clamping the hilum and also without formal renorrhaphy. However robust prospective formal evaluation of safety, risks, and potential benefits and whether o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/24/2025
Locations: University of Florida, Gainesville, Florida
Conditions: Renal Cell Carcinoma (RCC)
Register for Updates
Effect of the HCC Liver-Link Intervention
NCT06728293
Recruiting
Mortality rates for hepatocellular carcinoma (HCC) have risen in the US over the past two decades, disproportionately impacting Black patients with chronic liver disease5,6. Black patients are 50% less likely than White patients to receive curative therapies for HCC even when presenting with early stage disease7,8. Reasons for disparities in mortality are in part related to failure to progress through the complex HCC care continuum to access curative therapies as a result of the unequal distribu... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
06/24/2025
Locations: Indiana University School of Medicine, Indianapolis, Indiana
Conditions: HCC, Racial Disparities
Register for Updates
Long-term Potentiation Disruption Underlying Cognitive Impairment in ECT
NCT06733558
Recruiting
Cognitive problems, like memory loss, are common after brain injuries like trauma or stroke. These problems make daily life harder, and the investigators don't yet know the best ways to help the brain recover. Scientists think that a process in the brain called long-term potentiation (LTP) is important for memory and learning. When LTP isn't working properly, it may cause problems with thinking and memory. But studying LTP in people is hard because it happens deep inside the brain. Our research... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/24/2025
Locations: Domenici Hall, Albuquerque, New Mexico
Conditions: Major Depressive Disorder, Bipolar Disorder II
Register for Updates